INTRASENS Share Price Swiss Exchange
Equities
ALINS
FR0011179886
Advanced Medical Equipment & Technology
End-of-day quote
Other stock markets
|
||
- EUR | - |
04-17 | Intrasense: an innovative solution for cancer monitoring | CF |
04-09 | Guerbet: CE certificate for a platform | CF |
Sales 2022 | 3.79M 4.08M 326M | Sales 2023 | 3.3M 3.55M 285M | Capitalization | 18.8M 20.21M 1.62B |
---|---|---|---|---|---|
Net income 2022 | -3M -3.23M -258M | Net income 2023 | -3M -3.23M -258M | EV / Sales 2022 | 2.85 x |
Net Debt 2022 | 650K 699K 55.96M | Net cash position 2023 | 3.06M 3.29M 264M | EV / Sales 2023 | 4.76 x |
P/E ratio 2022 |
-2.97
x | P/E ratio 2023 |
-5.16
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 44.57% |
Managers | Title | Age | Since |
---|---|---|---|
Nicolas Reymond
CEO | Chief Executive Officer | 42 | 11/02/18 |
Julien Coste
DFI | Director of Finance/CFO | - | - |
Frédéric Champ
CTO | Chief Tech/Sci/R&D Officer | - | 28/02/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michèle Lesieur
CHM | Chairman | 65 | 07/10/20 |
Patrice Rullier
BRD | Director/Board Member | 63 | 14/03/19 |
Nicolas Reymond
CEO | Chief Executive Officer | 42 | 11/02/18 |
1st Jan change | Capi. | |
---|---|---|
+8.07% | 219B | |
+7.87% | 185B | |
+12.75% | 135B | |
+25.79% | 107B | |
+11.59% | 51.28B | |
+4.88% | 51.01B | |
+2.71% | 41.85B | |
+4.90% | 37.02B | |
+23.75% | 31.27B |
- Stock Market
- Equities
- ALINS Stock
- ALINS Stock